Jeffrey Harder, Ph.D.

Associate Computational Scientist

Biomedical scientist interested in uncovering the interactions between genes and environment that dictate the occurrence and form of disease.

I have a background in research and model development in glaucoma, diabetes, and COVID-19. My current interests include using single cell and spatial transcriptomic technologies to investigate disease mechanisms and improving translation of animal research using genetically diverse models and cross-species analyses.

Download cv

Selected Publications

53Harder JM, Guymer C, Wood JPM, Daskalaki E, Chidlow G, Zhang C, Balasubramanian R, Cardozo BH, Foxworth NE, Deering KE, Ouellette TB, Montgomery C, Wheelock CE, Casson RJ, Williams PA, John SWM. Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin. Proc Natl Acad Sci U S A. 2020 Dec 29; 117(52):33619-33627
67Harder JM, Williams PA, Braine CE, Yang HS, Thomas JM, Foxworth NE, John SWM, Howell GR. Complement peptide C3a receptor 1 promotes optic nerve degeneration in DBA/2J mice. J Neuroinflammation. 2020 Nov 11; 17(1):336
82Tribble JR, Harder JM, Williams PA, John SWM. Ocular hypertension suppresses homeostatic gene expression in optic nerve head microglia of DBA/2 J mice. Mol Brain. 2020 May 25; 13(1):81
118Williams PA, Braine CE, Kizhatil K, Foxworth NE, Tolman NG, Harder JM, Scott RA, Sousa GL, Panitch A, Howell GR, John SWM. Inhibition of monocyte-like cell extravasation protects from neurodegeneration in DBA/2J glaucoma. Mol Neurodegener. 2019 Jan 22; 14(1):6
48Harder JM, Williams PA, Soto I, Foxworth NE, Fernandes KA, Freeburg NF, Libby RT, John SWM. Jnk2 deficiency increases the rate of glaucomatous neurodegeneration in ocular hypertensive DBA/2J mice. Cell Death Dis. 2018 Jun 13; 9(6):705
28Williams PA, Harder JM, Cardozo BH, Foxworth NE, John SWM. Nicotinamide treatment robustly protects from inherited mouse glaucoma. Commun Integr Biol. 2018; 11(1):e1356956
103Williams PA, Harder JM, John SWM. Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma. J Glaucoma. 2017 Dec; 26(12):1161-1168
80Harder JM, Braine CE, Williams PA, Zhu X, MacNicoll KH, Sousa GL, Buchanan RA, Smith RS, Libby RT, Howell GR, John SWM. Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective. Proc Natl Acad Sci U S A. 2017 May 9; 114(19):E3839-E3848
54Williams PA, Harder JM, Foxworth NE, Cardozo BH, Cochran KE, John SWM. Nicotinamide and WLD(S) Act Together to Prevent Neurodegeneration in Glaucoma. Front Neurosci. 2017; 11:232
38Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, Smithies O, John SW. Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017 Feb 17; 355(6326):756-760
64Graham LC, Harder JM, Soto I, de Vries WN, John SW, Howell GR. Chronic consumption of a western diet induces robust glial activation in aging mice and in a mouse model of Alzheimer's disease. Sci Rep. 2016 Feb 18; 6:21568
232Fernandes KA, Harder JM, Williams PA, Rausch RL, Kiernan AE, Nair KS, Anderson MG, John SW, Howell GR, Libby RT. Using genetic mouse models to gain insight into glaucoma: Past results and future possibilities. Exp Eye Res. 2015 Dec; 141:42-56

View full list of publications

Research & Faculty

Education & Learning

JAX® Mice & Services

Personalized Medicine

News

About Us

Jeffrey Harder, Ph.D.

Associate Computational Scientist

Location

Contact

Topics

Selected Publications